Checkout our paired Perspective and Priority Brief in @CIR_AACR! Amazing collab with @carlhjune, @JoeFraietta and @GillSaar that we hope will help researchers, product developers and regulators advance gene edited T cell therapies.

Cell Therapy Keystone 2025 is coming! If you're interested in cell engineering, immunotherapy, cancer or autoimmunity (!) this meeting is for you! Join us in Banff for a fantastic symposium this March. Abstract deadline 12/9! @lab_rezvani .

RT @EricHolder: There is no cavalry coming. No miracle solution. No saviors. In the end, we, the American people-not any of our institut….

Incredibly creative work highlighting the broad applications of T cell immunotherapy - congrats Jony and team!.

Looking for a small meeting with leaders in cell therapy discussing high impact translational research? Look no further! The UChicago Jonas Center Symposium is for you! Please get in touch if you're interested or, better yet, register and join us! .

RT @BLLPHD: NEW - Regulatory Considerations for Genome-Edited T-cell Therapies, on navigating complexities in bringing new technologies to….

Taken the day @JoeBiden announced his candidacy in 2019. A patriot that history will remember for doing the right, hard thing, over and over. We are lucky to have had him as President. Now, let's kick it into gear for @VP @KamalaHQ and finish this!

RT @ElizSMcKenna: Now online in @CD_AACR: Rational Protein Engineering to Enhance MHC-independent T Cell Receptors - by Ju-Fang Chang, @Nat….

Huge shout out to Twitter-less Ju-fang Chang, our structural biologist extraordinaire who drove this work from start to finish, and the amazing editorial team @CancerDiscovery. (4/4).

Using advanced modeling tools, we alleviated these conflicts to enhance receptor function across a variety of tumor models. A clear demonstration that design of synthetic immunotherapies requires consideration of de novo protein structures. (3/4).

In our first foray into structural biology, we demonstrate that MHC-independent TCRs are riddled with structural and biochemical conflicts at hybrid domain interfaces, profoundly limiting function. (2/4).

Are all hybrid antigen receptors as easy to design as CARs? Definitely not! (1/4).

Huge shout out to @JoeFraietta, @carlhjune, Gerry Linette, Saar Gill and the team @CIR_AACR – a great experience collaborating with colleagues and editors to get these findings out to the community.

Importantly, we explore the unique challenges of TCR editing and provide guidance on how to approach this for each product’s specific needs. We hope this will serve as a toolbox to help scientists optimize their protocols and accelerate development of advanced T cell therapies.

Looking for the most effective ways to CRISPR edit human T cells? Look no further! Along with the team @Penn we identified the engineering steps that control product function. Nearly 10 years of troubleshooting with Cas9 and novel base editors distilled down into 4 figures! (1/4).

RT @sghorashian: Thanks for sharing our paper on the very low risk of T cell malignancies driven by insertional mutagenesis in a paediatric….

Check out the new Singh Lab website @ Huge shout out to the team @SciStories who was so amazing to work with.

Twitter fam! We are looking for a research associate to join our awesome team. If you know anyone interested in the interface of protein engineering, structural bio, gene editing and T cell immunotherapy please reach out! Also, please retweet and spread the word!.

These guys. Just killing it. Amazing progress in the most needed area!.